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Abstract
The anterior cingulate cortex (ACC) is a well-known brain area that is associated with pain perception. Previous studies reported
that the ACC has a specific role in the emotional processing of pain. Chronic pain is characterized by long-term potentiation that
is induced in pain pathways and contributes to hyperalgesia caused by peripheral nerve injury. The mammalian target of
rapamycin (mTOR) signaling, which is involved in synaptic protein synthesis, could be a key factor controlling long-term
potentiation in neuropathic pain conditions. Until now, there have been no reports that studied the role of mTOR signaling in
the ACC involved in neuropathic pain. Therefore, this study was conducted to determine the relationship of mTOR signaling in
the ACC and neuropathic pain. Male Sprague-Dawley rats were subjected to cannula implantation and nerve injury under
pentobarbital anesthesia. Microinjection with rapamycin into the ACC was conducted under isoflurane anesthesia on postoper-
ative day (POD) 7. A behavioral test was performed to evaluate mechanical allodynia, and optical imaging was conducted to
observe the neuronal responses of the ACC to peripheral stimulation. Inhibition of mTOR by rapamycin reduced mechanical
allodynia, down-regulated mTOR signaling in the ACC, and diminished the expressions of synaptic proteins which are involved
in excitatory signaling, thereby reducing neuropathic pain-induced synaptic plasticity. These results suggest that inhibiting
mTOR activity by rapamycin in the ACC could serve as a new strategy for treating or managing neuropathic pain before it
develops into chronic pain.
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Introduction
Neuropathic pain is induced by various causes, including tis-
sue or nerve damage, and is characterized by symptoms of
spontaneous pain, allodynia, and hyperalgesia [1]. Currently,
many therapies such as antidepressants and antiepileptics are
used to treat neuropathic pain, but these medications have side
effects and are not always effective [2–4]. Thus, the manage-
ment of neuropathic pain remains difficult. In the brain, corti-
cal areas that process information related to pain are known as
the Bpainmatrix,^which includes the anterior cingulate cortex
(ACC), insular cortex (IC), thalamus, somatosensory cortex,
and prefrontal cortex [1, 4, 5]. Among these regions, the ACC
is the main area associated with pain perception [6], and ac-
cumulating evidence implicates the involvement of the ACC
in the emotion processing of pain [7, 8].
Long-term potentiation (LTP) induced by repeated abnor-
mal sensory signaling after peripheral nerve injury is a prima-
ry feature of chronic pain in the central nervous system, and
the reinforcement of synaptic transmission is a core cellular
mechanism of chronic pain [9]. Such long-term synaptic plas-
ticity or central sensitization in the spinal cord and cortical
areas is known to contribute to chronic pain [10]. In addition,
changes in synaptic plasticity in the ACC are believed to be
essential for the development and maintenance of chronic pain
[9]. For instance, a brain imaging study found increased ACC
neuronal activity in persistent pain conditions [11], and animal
behavior studies employing acute and chronic pain models
showed that the development of LTP increases the number
of pre- and post-synaptic AMPA and NMDA receptors in
the ACC and that drugs that inhibit ACC activity exert anal-
gesic effects [12]. Therefore, these studies suggest that the
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ACC plays a vital role in processing pain-related information
and in behavioral responses to various stimuli including nox-
ious stimuli, inflammation, or nerve injury in humans and
animals. In addition, a study utilizing a peripheral amputation
model as well as an electrophysiological study reveals that
excitatory transmission in the ACC is strengthened after pe-
ripheral nerve injury [13, 14]. In a rodent model of neuropath-
ic pain, the development of allodynia is associated with syn-
aptic potentiation in the ACC 1–2 weeks after nerve injury
[15]. This finding suggests that neuropathic pain is associated
with mechanisms underlying the development of LTP in the
ACC. In addition, nerve damage could induce long-term en-
hancement of synaptic transmission in the ACC, which would
not only increase the release of neurotransmitters from pre-
synaptic terminals but also increase the number of postsynap-
tic receptors. Preventing, eliminating, or reducing enhance-
ment of excitatory transmission could be applied as a new
therapeutic method for suppressing chronic pain. Previous
studies show that neurons in the ACC respond to noxious
stimuli [16] and that lesioning the ACC significantly reduces
acute and neuropathic pain responses [17]. However, inhibi-
tion of pain transmission does not prevent chronic pain-related
synaptic strengthening, and drugs that suppress synaptic po-
tentiation do not affect acute or physiological pain [12].
Therefore, it is necessary to identify new therapeutic targets
for controlling chronic pain by investigating the induction and
formation mechanisms of pain-related LTP. LTP in chronic
pain can be classified into early LTP maintained by existing
proteins and late LTP (L-LTP) maintained through protein
synthesis [18, 19]. In particular, L-LTP contributes to long-
term changes in the cortical circuit due to synaptic protein
synthesis induced by peripheral nerve injury. Thus, the regu-
lation of protein synthesis may be an avenue for controlling
LTP, and LTP maintenance and formation could be regulated
by modulating mammalian target of rapamycin (mTOR),
which is involved in synaptic protein synthesis.
mTOR is a serine-threonine protein kinase that plays a
critical role in cell proliferation and differentiation in the ner-
vous system [20]. Activation of mTOR can be controlled
through various stimuli (e.g., neurotransmitters, growth fac-
tors, cytokines, oxygen, and amino acids) [21]. Activation of
mTOR affects transcription of mRNA in a variety of physio-
logical and pathologic pain states, including inflammatory and
cancer pain [22–26], by phosphorylating downstream factors
such as eukaryotic initiation factor 4E binding protein 1 (4E-
BP1) and p70 ribosomal S6 protein kinase (p70S6K) and is
reported to be involved in signal transduction through regula-
tion of protein synthesis [27]. mTOR can also regulate cell
growth, differentiation, and synaptic plasticity by activating
synaptic protein synthesis [19]. Thus, as LTP is maintained
through synaptic protein synthesis [20], the modulation of
synaptic protein synthesis through the regulation of mTOR
activation may play an important role in LTP changes.
Rapamycin, an mTOR inhibitor, has been used as an antican-
cer and immunosuppressive agent in the clinical treatment and
has relatively few side effects compared with other drugs [26,
28]. Recent studies suggest that rapamycin, which regulates
mTOR and its downstream effectors, could diminish chronic
inflammatory, neuropathic, and cancer pain. Studies also re-
port that mTOR activity is altered in a wide range of patho-
logical states, such as cancer, cardiovascular diseases, and
neurodegenerative disorders [26, 29, 30]. Pain behaviors
(e.g., mechanical hypersensitivity) are reduced when
rapamycin is intrathecally injected into hyperalgesia or in-
flammatory pain animal models or locally administrated in
neuropathic pain animal models [22–24]. The inhibition of
mTOR by treatment with the CCI-779, as confirmed by the
decreased expression of downstream signaling molecules in
the spinal cord and dorsal roots in a spared nerve injury animal
model, exerts a pain-relieving effect [31]. Previous studies
report that mRNA translation and local protein synthesis are
regulated by inhibiting mTOR activation in several pain
models [32, 33]. In addition, our laboratory found that
rapamycin reduces the expression of downstream signaling
molecules and synaptic proteins in the IC [34]. These previous
studies strongly suggest that mTOR plays an important role in
the modulation of long-term neuronal plasticity by preventing
the establishment of LTP. So far, the mTOR pathway has been
extensively studied in relation to cancer and described at the
spinal cord level in relation to inflammatory and neuropathic
pain, but only a few studies have been performed at the brain
level. Moreover, there were no studies that have reported pain
relief by controlling mTOR in the ACC of neuropathic pain
models until now. It is necessary to conduct further studies at
the brain level because the mTOR signaling pathway plays an
important role in the neuronal plasticity involved in pain pro-
cessing, such as the development of chronic pain. Therefore,
the purpose of the present study was to investigate the associ-
ation between pain caused by nerve injury and the mTOR
signaling pathway in the ACC and to test the pain-relieving
effect of rapamycin administration.
Materials and Methods
Experimental Animals
Adult male Sprague-Dawley rats that weigh 250–280 g
(Harlan, Koatec, Pyeongtaek, Korea) were used in the present
study. All animals were maintained under a 12-h light/dark
cycle with free access to food and water throughout the study
and were allowed to acclimate to the colony room for 7 days
after arrival. All experimental protocols were in compliance
with the National Institutes of Health guidelines and approved
by the Institutional Animal Care and Use Committee of
Yonsei University Health System (permit no. 2017-0148).
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Cannula Implantation
Rats were anesthetized with sodium pentobarbital (50 mg/kg,
i.p.) and placed in a stereotaxic frame. Stainless steel guide
cannulae (28-gauge) were bilaterally implanted into the ACC
(AP 1.5 mm from bregma, ML ± 0.6 mm from midline, DV
1.5 mm beneath the surface of the skull). The cannulae were
attached to the bone with stainless steel screws and acrylic
cement. Dummy cannulae were inserted into the guide cannu-
lae to avert clogging. Rats were allowed to recover for 7 days
after cannula implantation.
Neuropathic Surgery
A model of neuropathic pain was induced by ligation and
cutting of the sciatic nerve branches [35]. Under sodium pen-
tobarbital anesthesia, three terminal branches of the left sciatic
nerve were exposed by direct incision of the skin and a section
of the biceps femoris muscle. The tibial and sural nerves were
tightly ligated with 4-0 black silk and cut, and the common
peroneal nerve was left intact (nerve-injured; NP group).
Surgical procedures for the sham-operated group were identi-
cal to those for the NP group except that the nerves were not
injured. The neuropathic surgery and cannula implantation
were all performed on the same day.
Mechanical Allodynia Test
Rats were individually placed in small cages with a metal
mesh floor and habituated for 15 min before the test.
Mechanical allodynia was measured by assessing thresholds
for each hind paw withdrawal from stimulation by an elec-
tronic von Frey filament (UGO Basile, Varese, Italy). A sin-
gle, un-bending filament was vertically applied to the hind
paw, and licking or rapid withdrawal of the hind paw was
considered a positive response. Responses were measured
seven times in 2–3-min intervals. The mechanical allodynia
test was performed before nerve injury and on postoperative
days (PODs) 1, 4, 7, and 14 by a researcher blinded to exper-
imental conditions.
Rapamycin Microinjection into the ACC
Rapamycin (R-5000; LC Laboratories, Woburn, MA, USA)
was prepared in 0.06% dimethyl sulfoxide diluted in saline.
Microinjections were performed on POD 7. Rapamycin
(0.5 μl of 150, 300, and 600 nM per side over 1 min) or an
equivalent amount of vehicle solution was microinjected into
the ACC bilaterally via the injection cannulae, which were
lowered 1 mm deeper into the ACC than the guide cannulae.
The microinjection apparatus consisted of Hamilton syringes
(1 μl) connected to the injection cannulae with PE-10 tubing.
After injection, the injection cannulae were maintained in
place for at least 1 min to allow for drug absorption into the
brain and to minimize reflux along the track of the cannulae.
Additional mechanical allodynia tests for confirming the ef-
fect of drug administration were performed before and 0.5, 1,
2, 4, 8, 12, and 24 h after rapamycin or vehicle solution mi-
croinjection into the ACC by a researcher blinded to microin-
jection substance.
Western Blot Analysis/Tissue Collection
and Immunoblotting
Two hours after microinjection of rapamycin or vehicle solu-
tion on POD 7, rats were anesthetized with isoflurane and
decapitated for ACC tissue sample collection. The ACC (AP
+ 2.2 to − 1.2 from bregma) was dissected on ice using a rat
brain matrix (RWD Life Science, Shenzhen, China). Three
coronal brain slices (1 mm thick) containing the ACC were
dissected using a surgical blade and rapidly frozen in liquid
nitrogen. For protein extraction, samples were homogenized
in lysis buffer (ProPrep; Intron Biotechnology, Pyeongtaek,
Korea) containing phosphatase inhibitors (Phosstop; Roche,
Mannheim, Germany) and incubated on ice for 2 h. Samples
were then centrifuged at 15,000 rpm for 15 min at 4 °C, and
supernatants were collected. Total protein concentrations were
assessed with a spectrophotometer (Nano Drop ND-1000;
NanoDrop Technologies Inc., Wilmington, DE, USA), and
equal amounts of protein (30 mg per well) were denatured
and loaded on 10% SDS-PAGE (for mTOR, p-mTOR,
p70S6K, and p-p70S6K) and 15% SDS-PAGE (for 4E-BP1
and p-4E-BP1) (Bio-Rad, Hercules, CA, USA). Proteins were
transferred onto a polyvinylidene difluoride membrane
(Merck Millipore, Darmstadt, Germany). Phospho-proteins
were immunodetected first followed by the corresponding to-
tal protein after the blot was stripped. For enhanced visualiza-
tion and analysis of 4E-BP1 and p-4E-BP1, transferred pro-
teins were fixed to the membrane by 0.05% glutaraldehyde in
TBS-0.05% Tween-20 (TBST) for 15 min at room tempera-
ture [36]. Membranes were stained with Ponceau S (Sigma-
Aldrich, St. Louis, MO, USA), and staining of the wells was
visually compared. Membranes were blocked by incubation in
5% bovine serum albumin in TBST for 1 h at room tempera-
ture and incubation overnight at 4 °C with primary antibodies
diluted in 5% bovine serum albumin in TBST. The following
primary antibodies were used: mTOR (no. 2972, 1:1000; Cell
Signaling Technology, Beverly, MA, USA), p-mTOR (Ser
2448, no. 2971, 1:500; Cell Signaling Technology), p70S6K
(no. 2708, 1:1000; Cell Signaling Technology), p-p70S6K
(Thr 389, no. 9205, 1:500; Cell Signaling Technology), 4E-
BP1 (no. 9644, 1:1000; Cell Signaling Technology), p-4E-
BP1 (Thr37/46, no. 2855, 1:500; Cell Signaling
Technology), and β-actin (no. 3700, 1:15,000; Cell
Signaling Technology). The next day, blots were washed three
times in TBST and incubated with the appropriate anti-rabbit
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horseradish peroxidase-conjugated secondary antibody (no.
7074 , 1 : 10 , 000 ; Ce l l S i gna l i ng Techno l ogy ) .
Immunoreactive proteins were visualized by applying a
chemiluminescent (ECL) detection reagent (GE Healthcare,
Little Chalfont, UK) and observed using an LAS system
(LAS 4000, GE Healthcare, Fuji Film Inc., Tokyo, Japan).
Phospho-protein and total protein immunoreactivity was
scanned and quantified using Multi-gage software (Fuji Film
Inc., Tokyo, Japan). Each value was normalized to the respec-
tive β-actin band, and optical density was divided by that of
the corresponding total protein band to yield a phospho-pro-
tein/total protein ratio.
Immunohistochemistry
On POD 7, rats were deeply anesthetized with urethane
(1.25 g/kg, i.p.) immediately after mechanical allodynia test-
ing following microinjection of rapamycin or vehicle solution
into the ACC and perfused transcardially with normal saline
(0.9% NaCl) via the ascending aorta followed by a 4% solu-
tion of formaldehyde in 0.1 M sodium phosphate buffer
(pH 7.4). Brains were removed, post-fixed in the same para-
formaldehyde solution for 4 h at 4 °C, and immersed in a 10 to
30% (w/v) sucrose gradient in phosphate-buffered saline
(PBS; pH 7.4) for 24–48 h at 4 °C for cryoprotection. After
cryoprotection, brains were embedded in optimal cutting tem-
perature compound (Sakura Finetek USA Inc., Torrance, CA,
USA) and cut on a cryostat (Microm HM525; Thermo
Scientific, Waltham, MA, USA) into 20-μm-thick coronal
sections. Double immunofluorescence staining for PSD-95/
AMPAR GluA1 subunits or PSD-95/NMDAR NR2B sub-
units was performed. Sections containing the ACC were
blocked in PBS containing 0.3% Triton X-100 (PBST) and
5% normal donkey serum for 2 h at room temperature. For
double immunofluorescence, sections were incubated over-
night with a mixture of mouse anti-PSD-95 (1:500, ab2723,
Abcam, Cambridge, UK) and rabbit AMPA GluA1 (1:500,
ab31232, Abcam) or rabbit anti-NMDAR2B (1:500,
ab65783, Abcam) antibodies in PBST containing 5% normal
donkey serum at 4 °C. All sections were rinsed with PBST
(5 min, three times) after each step. After rinsing, sections
were incubated with Cy3-conjugated donkey anti-mouse
I g G (H + L ) ( 1 : 2 0 0 , 7 1 5 - 1 6 5 - 1 5 0 , J a c k s o n
ImmunoResearch, West Grove, PA, USA) or Alexa Fluor
488-conjugated donkey anti-rabbit IgG (H + L) (1:200, 711–
545-152, Jackson ImmunoResearch) secondary antibody for
2 h at room temperature. Sections were mounted with
Vectashield containing DAPI to label nuclei (Vector
Laboratories, Youngstown, OH, USA). In each experiment,
sections from different groups were stained at the same time.
High-magnification fluorescent images were taken with a
Zeiss LSM 700 confocal microscope (Carl Zeiss, Jena,
Germany). Quantitative assessment of PSD-95 and AMPAR
or NMDAR immunoreactivity was performed using the
ImageJ 1.46r software program (National Institutes of
Health, Bethesda, Maryland, USA). In addition, the total num-
ber of pixels of the stained area was quantified and expressed
as immunodensity. These measurements were performed
using two sections randomly selected from the five serial sec-
tions of the ACC from each animal. Immunodensities were
averaged to obtain a single value for each rat.
Optical Imaging
Before imaging, rats were deeply anesthetized with urethane
(1.25 g/kg, i.p.) on POD 7 and given atropine (5 mg/kg, i.p.)
to suppress mucus secretion and dexamethasone sulfate (1 mg/
kg, i.p.) to reduce swelling of the brain. Rats were then placed
in a custom-made stereotaxic frame to stabilize the head during
optical imaging. Lidocaine was applied to the skin, and a cra-
niotomy was made that extended AP + 6 to − 2 mm from breg-
ma andML ± 4 mm frommidline. The dura over the ACC was
carefully removed. To expose the ACC, double closure of the
superior sagittal sinus was performed using 4–0 black silk, and
the superior sagittal sinus was then cut with microscissors and
separated from the cortex. If slight bleeding occurred, it was
easily controlled using a saline-moistened cotton compress.
This surgical procedure was slightly modified from that de-
scribed for a rat pinealectomy study and an electrophysiological
study [37, 38]. The exposed ACC was stained using voltage-
sensitive dye (di-2-ANEPEQ, 50 mg/mL in saline; Molecular
Probes, Eugene, OR, USA) for 1 h and carefully rinsed with
saline. Imaging was performed before and after application of
600 nM rapamycin or vehicle solution directly to the exposed
cortex for 30 min. Heart rate was monitored by electrocardiog-
raphy, and body temperature was maintained at 36 °C with a
rectal probe and heating pad system (Homeothermic Blanket
Control Unit; Harvard Apparatus, Holliston, MA, USA).
A pair of stainless steel electrodes was inserted into the left
hind paws where the electronic von Frey filaments had been
applied during behavioral testing. Stimulation of the hind paw
was done with square pulses (width 0.1 ms, interstimulus in-
terval 5 s, intensity 2.5 mA) using a stimulus isolation unit
(World Precision Instruments, Sarasota, FL, USA). Changes
in fluorescence after peripheral stimulation were measured
using a high-resolution CCD camera (Brainvision Inc.,
Tokyo, Japan) equipped with a dichroic mirror with a 510–
550-nm excitation filter and 590-nm absorption filter. A tung-
sten halogen lamp (150W) was used for excitation of fluores-
cence. The imaging area was 6.4 × 4.8 mm2 and consisted of
184 × 124 pixels. The fluorescence intensity during each trial
was detected for approximately 940 ms under an optical mi-
croscope (Leica Microsystems Ltd., Heerbrugg, Switzerland)
equipped with a ×1 objective and ×1 projection lens. Optical
signals were acquired at a rate of 3.7 ms/frame, and averages
of 20 trials were recorded by an optical imaging recording
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system (MiCAM02; Brainvision Inc.). Optical imaging acqui-
sition was triggered by electrocardiogram signals using a
stimulus/non-stimulus subtraction method. After optical im-
aging, rats were euthanized by an overdose of urethane. To
normalize the value of each pixel, the ratio of the intensity of
fluorescence (ΔF) in each pixel relative to the initial fluores-
cence intensity (F) was expressed as a fractional change (ΔF/
F). Amplitudes and excitatory areas of optical signals were
measured using a spatial filter (9 × 9 pixels) to reduce artifacts
caused by vibration and brain movements. Using captured
images, fractional changes in optical signals (i.e., optical in-
tensity) and areas of activation were quantified. Changes in
optical intensity in the ACCwere expressed as a percentage of
fractional change in fluorescence (%ΔF/F). Activated areas
were analyzed using the activated pixel number divided by the
total pixel number in the region of interest (AP + 2.2 to +
0.2 mm from bregma) × 100. Data were collected and ana-
lyzed with BVAnalyzer software (Brainvision Inc.).
Statistical Analysis
Statistical analyses were performed using SPSS 20.0 software
(IBMCorporation, Armonk, NY, USA). Behavioral data were
analyzed by two-way repeated measures analysis of variance
(ANOVA) followed by Bonferroni’s test for post hoc compar-
isons. Western blotting and immunohistochemistry data were
analyzed by one-way ANOVA followed by Tukey’s test for
multiple comparisons. Optical imaging data were analyzed by
paired t test. All values are expressed as mean ± standard error
of the mean (SEM). Values of p < 0.05 were considered sta-
tistically significant.
Results
Development of Mechanical Allodynia Induced
by Nerve Injury
To confirm the development of mechanical allodynia, we ex-
amined hind-paw withdrawal threshold in our neuropathic
pain animal model using the electronic von Frey 1, 4, 7, and
14 days after neuropathic pain surgery (Fig. 1a). From POD 1
to POD 14, withdrawal threshold was significantly decreased
in the NP group (n = 6) compared with the control (Sham)
group (n = 6; for nerve injury F1,70 = 703.223, p < 0.001; for
POD F4,70 = 55.943, p < 0.001; for nerve injury × POD
F4,70 = 54.038, p < 0.001; two-way repeated measures
ANOVA followed by Bonferroni test, Fig. 1b). However,
there was no significant difference between groups before
surgery.
Nerve Injury Activates mTOR Signaling in the ACC
Based on our behavioral results, we hypothesized that mTOR
signaling in the ACC would be altered during the develop-
ment of chronic pain after nerve injury. To confirm this hy-
pothesis, we examined the mTOR signaling pathway using
western blot analysis. We measured total and phosphorylated
protein levels of mTOR and its downstream effectors,
P70S6K and 4E-BP1, in the ACC 1, 4, 7, and 14 days after
nerve injury (POD 1, POD 4, POD 7, and POD 14) as well as
in normal and sham injury groups. We found that phosphory-
lated mTOR (p-mTOR) was significantly up-regulated in the
POD 7 group compared with the normal group (n = 6; F5,30 =
Fig. 1 Electronic von Frey test and development ofmechanical allodynia.
a Illustration of electronic von Frey test for assessing mechanical
withdrawal threshold. Rats were individually placed on a metal mesh
floor in small plastic cages. A filament was vertically applied to a hind
paw, and force was measured until paw withdrawal occurred and was
displayed by the device. b Development of mechanical allodynia in
nerve-injured (NP) and sham-injured (Sham) rats. After nerve injury,
significantly lower mechanical withdrawal thresholds were observed in
the NP group on POD 1, 4, 7, and 14 compared with those in the Sham
group. Data are presented as mean ± standard error of mean (SEM). **p
< 0.01 vs. Sham, two-way repeated measures analysis of variance
(ANOVA) followed by Bonferroni test
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5.456, p = 0.001, one-way ANOVA followed by Tukey’s mul-
tiple comparison test, Fig. 2a). Furthermore, levels of p-
p70S6K and p-4E-BP1 were significantly elevated in POD 7
group compared with the normal group (n = 6; F5,30 =
3.669, p = 0.010 and F5,30 = 2.908, p = 0.029, respective-
ly, one-way ANOVA followed by Tukey’s multiple
comparison test, Fig. 2b, c), whereas there were no
group differences in the total forms of these proteins (p =
0.849, one-way ANOVA). Thus, activation of mTOR and its
downstream effectors in the ACC gradually increased after
nerve injury and peaked on POD 7. However, expression of
p-mTOR, p-p70S6K, and p-4E-BP1 declined slightly between
POD 7 and POD 14.
Microinjection of Rapamycin into the ACC Diminishes
Mechanical Allodynia After Nerve Injury
After the establishment of mechanical allodynia, rapamycin
(150, 300, or 600 nM; n = 8) or vehicle (n = 8) was injected
into the ACC (Fig. 3a). Mechanical sensitivity was examined
0.5, 1, 2, 4, 8, 12, and 24 h after injection. All rapamycin-
injected groups showed a reduced response to mechanical
stimulation as measured in the von Frey test (n = 8; for drug
(vehicle or rapamycin): F3,224 = 74.272, p < 0.001; for time
(after drug injection): F7,224 = 22.196, p < 0.001; for drug ×
time: F21,224 = 16.427, p < 0.001; two-way repeated measures
ANOVA followed by Bonferroni test, Fig. 3b). The response
to mechanical stimulation in the 150 nM rapamycin group
significantly increased from 0.5 to 1 h (0.5 and 1 h: p <
0.001 vs. vehicle group, two-way repeated measures
ANOVA followed by Bonferroni test), and the analgesic effect
of 300 nM rapamycin persisted from 0.5 to 4 h (0.5 to 2 h: p <
0.001, 4 h: p = 0.026 vs. vehicle group, two-way repeated
measures ANOVA followed by Bonferroni test). However,
600 nM rapamycin was the most effective dose (0.5 to 8 h:
p < 0.01, 12 h: p = 0.013 vs. vehicle group, two-way repeated
measures ANOVA followed by Bonferroni test). No change in
withdrawal threshold to mechanical stimuli was observed in
the vehicle group during the 24 h after microinjection (p =
0.749, two-way repeated measures ANOVA).
Microinjection of Rapamycin into the ACC Blocks
Activation of mTOR and its Downstream Effectors
in the ACC After Nerve Injury
We next confirmed changes in the mTOR signaling pathway
after rapamycin injection by western blot analysis. As the
highest paw withdrawal threshold was reached 2 h after
600 nM rapamycin injection and persisted to 4 h, we collected
ACC tissue 2 h after rapamycin or vehicle microinjection on
POD 7 and measured the expression of mTOR and its down-
stream effectors. The levels of p-mTOR, p-p70S6K, and p-4E-
BP1 in the vehicle group were significantly higher than those
in the Sham group (p-mTOR F4,35 = 5.164, p = 0.035; p-
p70S6K F4,35 = 3.568, p = 0.022; and p-4E-BP1 F4,35 =
3.313, p = 0.027, one-way ANOVA followed by Tukey’s mul-
tiple comparison test, Fig. 4a–c), and the rapamycin groups
tended to exhibit a gradual decrease in phospho-protein levels
in a dose-dependent manner. In particular, the level of p-
mTOR in the 600 nM rapamycin group was significantly low-
er than that in the vehicle group (p = 0.008, one-way ANOVA
followed by Tukey’s multiple comparison test, Fig. 4a). In
addition, p-p70S6K and p-4E-BP1 expression was signifi-
cantly lower than that in the vehicle group (p = 0.048 and
p = 0.038, respectively, one-way ANOVA followed by
Tukey’s multiple comparison test, Fig. 4b, c), but there were
no changes in total protein levels (p = 0.632, one-way
ANOVA).
Fig. 2 Activation of mTOR and its downstream effectors in the ACC
after nerve injury. a–c Expression levels of p-mTOR, p-p70S6K, and p-
4E-BP1 after nerve injury. Levels of p-mTOR, p-p70S6K, and p-4E-BP1
gradually increased after nerve injury as shown by western blot analysis.
Seven days after nerve injury (POD 7), p-mTOR, p-p70S6K, and p-4E-
BP1 expression were significantly up-regulated compared with the
normal group, but all phospho-protein levels declined 14 days after
nerve injury (POD 14) as compared with the POD 7 group. Total
protein levels in all groups did not change over time. Data are presented
as mean ± SEM. *p < 0.05, **p < 0.01 vs. normal, one-way ANOVA
followed by Tukey’s multiple comparison test
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Inhibition of mTOR Suppresses Synaptic Protein
Expression in the ACC After Nerve Injury
To determine the effect of rapamycin-induced inhibition of
mTOR signaling on synaptic protein synthesis, we performed
immunofluorescence staining. We observed changes in the co-
localization relative intensity of PSD-95 and glutamate receptors
(AMPAR GluA1 subunit or NMDAR NR2B subunit) in the
ACC 2 h after rapamycin or vehicle microinjection on POD 7.
Figure 5a shows location of the ACC used for staining analysis.
Cg1 indicates cingulate cortex, area 1 in the rat brain atlas.
AMPAR-PSD-95 and NMDAR-PSD-95 co-localization were
markedly increased in ACC layer II/III after peripheral nerve
injury (Fig. 5b, c). Moreover, rapamycin injection resulted in a
dose-dependent reduction in the percentage of co-localization
relative intensity of PSD-95 and glutamate receptors in the
ACC compared with that in the vehicle group. Specifically,
AMPAR-PSD-95 co-localization was significantly lower in the
Fig. 3 Microinjection of rapamycin into the ACC attenuates mechanical
hypersensitivity. a Stereotaxic location of rapamycin microinjection into
the ACC. Red dots point at microinjection sites and Cg1 indicates
cingulate cortex, area 1 in the rat brain atlas. Stainless steel guide
cannulae for drug microinjection were bilaterally implanted into the
ACC. b Changes in paw withdrawal threshold to mechanical
stimulation after microinjection of rapamycin or vehicle on POD 7.
Significant differences in withdrawal threshold between 150 nM
rapamycin and vehicle groups were observed between 0.5 and 1 h after
microinjection. Withdrawal thresholds in the 300 nM rapamycin group
were significantly elevated between 0.5 and 4 h after microinjection. The
most pronounced changes in withdrawal threshold were observed in the
600 nM rapamycin group, with significant changes observed between 0.5
and 8 h after microinjection. Data are presented as mean ± SEM. *p <
0.05; **p < 0.01 vs. vehicle, two-way repeated measures ANOVA
followed by Bonferroni test
Fig. 4 Microinjection of rapamycin into the ACC suppresses activation
of mTOR and its downstream effectors after nerve injury. a–c Expression
of p-mTOR, p-p70S6K, and p-4E-BP1 after microinjection of rapamycin.
Levels of p-mTOR, p-p70S6K, and p-4E-BP1 were significantly
increased in the vehicle group compared with the Sham group and
significantly decreased in all rapamycin groups (Rapa) compared with
the vehicle group in a dose-dependent manner. Levels of p-mTOR, p-
p70S6K, and p-4E-BP1 were most prominently reduced in the 600 nM
rapamycin group compared with the vehicle group. Total protein levels
were similar among groups. Data are presented as mean ± SEM. *p <
0.05; **p < 0.01 vs. Sham; #p < 0.05 vs. vehicle, one-way ANOVA
followed by Tukey’s multiple comparison test
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600 nM group than in the vehicle group (F4,25 = 29.331, p <
0.001, one-way ANOVA followed by Tukey’s multiple compar-
ison test, Fig. 5d), and NMDAR-PSD-95 co-localization was
significantly lower in the 300 nM and 600 nM groups than in
the vehicle group (F4,25 = 46.517, p < 0.001, one-way ANOVA
followed by Tukey’s multiple comparison test, Fig. 5e).
Fig. 5 Synaptic protein expression after inhibition of mTOR signaling in
the ACC. a Location of the ACC used for staining analysis. Cg1 indicates
cingulate cortex, area 1 in the rat brain atlas and red squire indicates
location for staining analysis. b Different sets of ACC tissue treated
with rapamycin (Rapa) or vehicle on POD 7 were subjected to
immunofluorescence staining with anti-PSD-95 (red), anti-GluA1
(green) or anti-NR2B (green), and DAPI (blue). Representative
immunofluorescence staining of PSD-95, AMPA receptor GluA1
subunit, and nuclei (DAPI). c Representative immunofluorescence
staining of PSD-95, NMDA receptor NR2B subunit, and nuclei
(DAPI). Scale bar = 10 μm. d Percentage of co-localization relative
intensity of PSD-95 and AMPA GluA1 receptor subunit expression.
The percentage was significantly higher in the vehicle group than in the
Sham group, and the percentages in the Rapa groups declined in a dose-
dependent manner. The 600-nM group showed a significant decrease
compared with the vehicle group. e Percentage of co-localization
relative intensity of PSD-95 and NMDA NR2B receptor subunit
expression. The percentage was significantly higher in the vehicle
group than in the Sham group, and the percentages in the Rapa groups
declined in a dose-dependent manner. The 300- and 600-nM groups
showed significant decreases compared with the vehicle group. Data are
presented as mean ± SEM. **p < 0.01 vs. Sham; ##p < 0.01 vs. vehicle,
one-way ANOVA followed by Tukey’s multiple comparison test
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Inhibition of mTOR Reduces Excitability in the ACC
Induced by Peripheral Stimulation
Optical imaging using voltage-sensitive dye is a convenient
approach to measuring cortical activity after peripheral
stimulation. In the present study, we imaged the ACC of
nerve-injured rats to detect optical signal changes after elec-
trical stimulation of the hind paw. To investigate differences in
spatiotemporal patterns in the ACC of sham (Sham) versus
nerve-injured (NP) rats, we exposed the cortex (Fig. 6a) and
Fig. 6 Changes in optical signals in the ACC. a Dorsal view of the
exposed cortex and representative image. The inner area of the dotted
red lines indicates the ACC region. b Representative optical images and
signals in the ACC from sham-injured (Sham, upper) and nerve-injured
(NP, lower) rats. Red arrows indicate time point of electrical stimulation.
NP rats showed a larger activated area in the ACC and increased peak
amplitude after peripheral stimulation (2.5 mA) compared with Sham
rats. Scale bar = 1 mm. c, d Optical signals from NP rats before and
after vehicle or 600 nM rapamycin treatment. Blue lines mean before
treatment and red lines mean after treatment in the optical signals. e, f
Peak amplitudes and activated areas before and after vehicle or rapamycin
treatment following peripheral electrical stimulation (2.5 mA). The peak
amplitude and activated area induced by peripheral electrical stimulation
after rapamycin treatment were significantly lower than those before
rapamycin treatment. However, they were similar before and after
vehicle treatment. Data are presented as mean ± SEM. *p < 0.05; **p <
0.01, paired t test
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obtained representative optical images after electrical stimula-
tion of the contralateral hind paw (Fig. 6b). Color-coded im-
ages in the left side of Fig. 6b are optical signals of the acti-
vated ACC induced by peripheral stimulation based on frac-
tional changes in reflected light intensity (%ΔF/F), and wave
forms in the right side of Fig. 6b show optical responses at
specific points in the ACC. Whereas the ACC of NP rats
showed optical responses, little change in optical signals and
wave forms in the ACC were found after 2.5 mA electrical
peripheral stimulation in Sham rats.
Optical images of responses to peripheral stimulation be-
fore and after rapamycin treatment are shown in Fig. 6c, d.
Figure 6c, d shows representative images before and after
vehicle treatment or 600-nM rapamycin treatment, respective-
ly, following 2.5-mA electrical peripheral stimulation in
nerve-injured rats. As we found a maximal pain-relieving ef-
fect of 600 nM rapamycin injection, we used 600 nM
rapamycin to validate neural activity in the ACC. After
rapamycin treatment, neuronal activity in the ACC was strik-
ingly reduced compared with that before treatment. Peak am-
plitudes induced by peripheral electrical stimulation were re-
duced after rapamycin treatment compared with before
rapamycin treatment (t5 = 5.07, p = 0.003, paired t test, Fig.
6e). Also, the area of activation was reduced after rapamycin
treatment compared with before rapamycin treatment (t5 =
8.069, p < 0.001, paired t test, Fig. 6f). By contrast, peak am-
plitude and activated area were not significantly different be-
fore and after vehicle treatment (p = 0.838 and p = 0.443 re-
spectively, paired t test).
Discussion
Changes in synaptic plasticity in many areas of the central
nervous system are involved in pain processing and chronic
pain, including the spinal cord, cortical areas, and subcortical
areas [10, 12]. Previous studies show that changes of neural
plasticity in the ACC are associated with persistent pain and
fear memory in a mouse model [39]. ACC neurons respond to
nociceptive and non-nociceptive mechanical or thermal so-
matosensory stimuli as well as emotional aspects of pain [16,
40, 41]. In particular, nociceptive information is projected to the
ACC from other pain-related regions, such as the medial thal-
amus, amygdala, and other pain-related area of the cortex [42].
Recently, mTOR has been found to control cancer, inflam-
matory, and neuropathic pain [24, 26, 31, 43]. These studies
provide evidence that mTOR plays an important role in pain
management but have mainly focused on mechanisms at the
spinal level. The present study validated the role of mTOR sig-
naling at the brain level by examining mechanical hyperalgesia
and changes in the expression of activated mTOR (p-mTOR)
and its downstream effectors (p-p70S6K and p-4E-BP1) in the
ACC after nerve injury in an animal model of neuropathic pain.
Our results suggest that the development of neuropathic pain
induced by peripheral nerve injury is associated with increased
activity of mTOR and its downstream effectors in the ACC.
Previous studies report increased activity of mTOR and its
downstream effectors in the spinal cord dorsal horn in the chron-
ic constriction injury model [44], the rostral ventromedial me-
dulla in the spared nerve injury model [45], and the IC in the
nerve-injured model [34]. Also, another study reports increased
expression of p-mTOR and p-p70S6K in the ACC of a
formalin-induced inflammatory animal model [46]. Together
with previous studies, our results demonstrate that the mTOR-
dependent signaling pathway in the ACC is involved in the
development of chronic pain. In addition, the expressions of
activated mTOR and its downstream effectors on POD 14 were
less than on POD 7. The differences in the expression levels on
POD 14 and POD 7 might indicate that the mTOR signaling
pathway in theACCbecomes less effective inmaintaining nerve
injury-induced chronic pain.
Previous electrophysiological studies show that rapamycin,
an mTOR inhibitor, inhibits L-LTP in the hippocampus when
delivered during LTP induction but not after LTP formation
[18, 47]. Also, intrathecal injection of rapamycin reduces me-
chanical hyperalgesia behaviors and decreases phosphorylation
of mTOR and its downstream effectors in the spinal cord dorsal
horn in chronic constriction injury and spinal cord injury animal
models [22, 44]. These results indicate that neuropathic pain
could be regulated by rapamycin. In the present study, mechan-
ical allodynia was significantly reduced after microinjection of
rapamycin into the ACC, and levels of phosphorylation of
mTOR, p70S6K, and 4E-BP1 were significantly decreased in
a dose-dependent manner. In particular, 600 nM rapamycin was
the most effective dosage for reducing mechanical allodynia
and phosphorylation of mTOR, p70S6K, and 4E-BP1.
Previous studies have reported that rapamycin decreases pain
behaviors in a dose-dependent manner without a change in
locomotor activity and apparent adverse effects [48–50].
Thus, these results suggest that rapamycin reduces pain-
related behaviors by inhibiting the activation of mTOR.
mTOR regulates synaptic protein transcription via many
factors [51]. Activation of mTOR regulates the phosphoryla-
tion of downstream effectors such as p70S6K and 4E-BP1,
which in turn regulate mRNA translation and protein synthe-
sis [27, 52] and thereby affect protein translation [22]. Local
protein synthesis in axons and dendrites contributes to regu-
lating long-lasting synaptic plasticity, neurite development,
and response to nerve injury [53, 54]. It is well-known that
mTOR regulates local transcription of mRNA through phos-
phorylation of p70S6K and 4E-BP1 [47]. Phosphorylation of
p70S6Kmediates translation initiation and polypeptide exten-
sion, whereas phosphorylation of 4E-BP1 reduces cap-
dependent transcription by inhibiting eukaryotic initiation fac-
tor 4E (eIF4E) [52]. Activation of mTOR signaling induces
dendritic protein synthesis, including the synthesis of
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postsynaptic glutamate receptors and postsynaptic density
proteins necessary for maintaining long-lasting forms of syn-
aptic plasticity, especially L-LTP [52, 55]. A previous study
has shown that intrathecally administered rapamycin reduces
expression levels of activated mTOR and its downstream effec-
tors in the spinal dorsal horn at 7 days, but not 14 days, after
nerve injury [44]. This finding agrees well with our observa-
tions showing that expression levels of p-mTOR in the ACC
increased on 7 days after nerve injury and declined thereafter.
We have also observed that inhibition of mTOR signaling by
rapamycin injected bilaterally into the ACC on POD 7 reduced
nerve injury-induced pain behavior. Thus, it is suggested that
during the development of chronic pain, activation of mTOR
signaling is necessary to express pain behaviors. In addition,
activation of postsynaptic receptors affects the development of
chronic hyperalgesia to noxious stimuli [56]. Post-synaptic
density (PSD), which binds to postsynaptic receptors and ad-
hesion molecules, is maintained by an abundant set of scaffold
proteins and has a role in mediating activation of synaptic re-
ceptors for biochemical signaling events in post-synaptic neu-
rons [57]. In particular, the interaction between the NMDA
receptor NR2B subunit and PSD-95 plays an important role
in synaptic plasticity in the central nervous system underlying
the development of neuropathic pain after peripheral nerve in-
jury [14]. The AMPA receptor GluA1 subunit also contributes
to pain-related LTP expression in the ACC [58]. Thus, it is
possible that the mTOR pathway induces long-term changes
in synaptic efficacy by facilitating interaction of glutamate re-
ceptors with PSD proteins, leading to the long-lasting synaptic
plasticity associated with chronic pain.
Here, we provide strong evidence that mTOR contributes
to neuropathic pain induced by peripheral nerve injury by
increasing the excitability of pyramidal neuron in the ACC.
Our immunofluorescence staining showed that the expression
of PSD-95 was increased at apical dendrites of ACC pyrami-
dal neurons after nerve injury and confirmed increased inter-
actions between PSD-95 and glutamate receptors (AMPAR
GluA1 and NMDARNR2B subunits). In addition, rapamycin
administration into the ACC decreased the expression of and
interaction between these synaptic proteins. These results
demonstrate that rapamycin suppresses the activity of
mTOR and its downstream effectors, thereby decreasing
translation and synthesis of mTOR-mediated synaptic pro-
teins. Because both the ACC and primary somatosensory cor-
tex, which are located in the pain ascending pathway, receive
nociceptive inputs from the medial thalamus, the increased
activity of pyramidal cells in both areas reflects their partici-
pation in a cerebral cortical circuit involved in chronic pain. In
fact, electrophysiological studies show the activation of many
pyramidal neurons of ACC layer II/III after nerve injury [59,
60], and some studies show that inhibiting the hyperactivity or
plasticity of pyramidal neurons in the ACC lessens the devel-
opment of chronic pain [59, 61]. Combining our current
results with those of previous studies, we speculated that
rapamycin modulates the interaction between GluA1-PSD-
95 and NR2B-PSD-95 by regulating the mTOR signaling
pathway that controls synaptic plasticity in the ACC. In other
words, mTOR signaling in the ACC is an important compo-
nent in neuropathic pain induced by nerve damage.
We performed optical imaging using voltage-sensitive dye
as an additional means to verify neuronal activation of the
ACC in neuropathic pain and to demonstrate changes in neu-
ronal activity after rapamycin treatment. This electrophysio-
logical technique allows the recording of membrane potential
changes to provide visual confirmation of the activity of the
neuronal population [62]. We delivered electrical stimuli to
hind paws to observe changes in nerve activity after
rapamycin treatment in the ACC of an animal nerve injury
model. Our results indicate that the ACC of neuropathic rats
was extensively activated in response to peripheral electrical
stimulation, and this ACC activation was diminished by
rapamycin. In other words, excitability in the ACC after nerve
injury decreased after treatment with an mTOR inhibitor.
Previous studies report similar results in the IC, which is also
involved in pain processing [34]. These findings, together
with those of previous studies, indicate that rapamycin could
reduce the response to peripheral stimulation before the devel-
opment of LTP. The purpose of this study was to validate the
efficacy of inhibiting mTOR activation in the ACC in reliev-
ing neuropathic pain caused by nerve injury. Consistent with
previous studies, our findings suggest that protein synthesis,
which maintains a chronic pain state, is suppressed by
inhibiting the activity of mTOR prior to LTP development.
However, the effect of pain relief did not persist more than
24 h after rapamycin microinjection; therefore, future studies
investigating the maintenance of this effect are needed. In
conclusion, the present study suggests that the mTOR path-
way in the ACC is an important avenue for controlling neu-
ropathic pain produced by peripheral nerve damage and pro-
vides evidence for a vital role of synaptic plasticity in the ACC
in the processing of pain.
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